Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Colon Cancer | Research article

RETRACTED ARTICLE: MiR-200c/FUT4 axis prevents the proliferation of colon cancer cells by downregulating the Wnt/β-catenin pathway

Authors: Jinchun Cong, Jian Gong, Chuanjia Yang, Zhixiu Xia, Hong Zhang

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

MicroRNA (miR)-200c has been widely reported to be involved in colon cancer progress. However, the mechanisms of miR-200c in regulating tumor metastasis and growth remain to be fully elucidated. This study aimed to investigate the mechanism of miR-200c targets fucosyltransferase 4 (FUT4) on the proliferation of colon cancer.

Methods

The miR-200c and FUT4 mRNA levels in LoVo and SW480 cells were measured by real-time quantitative polymerase chain reaction. Further, miR-200c mimic, FUT4 siRNA and FUT4 mimic were transfected into cells, separately. Cell counting kit-8, plate colony formation and transwell assays were used to analyse the cells biological behaviour.. Immunofluorescence was used to analyse the Ki-67 expression Moreover, the Wnt/β-catenin pathway-related proteins were detected by western blots. A double luciferase experiment was performed to confirm the relationship between miR-200c and FUT4. In vivo, tumour growth and Wnt/β-catenin pathway-related proteins were also analysed.

Results

In vitro, the expression of miR-200c and FUT4 were negatively correlated in LoVo and SW480 cells (correlation coefficients were − 0.9046 and − 0.9236, respectively). MiR-200c overexpression inhibited the proliferation, migration and invasion of LoVo and SW480 cells by downregulating FUT4. The Ki67-positive cells and Wnt/β-catenin signalling pathway-related proteins were reduced in the miR-200c overexpression and FUT4 silencing groups. A dual luciferase reporting system identified FUT4 as the target of miR-200c. The results in vivo were further confirmed the foundation of cells study.

Conclusions

In summary, miR-200c overexpression inhibits proliferation of colon cancer targeting FUT4 to downregulate the Wnt/β-catenin pathway, which promises molecular targets to inhibit metastasis for colon cancer therapy.
Appendix
Available only for authorised users
Literature
1.
Zeng M, Zhu L, Li L, Kang C. miR-378 suppresses the proliferation, migration and invasion of colon cancer cells by inhibiting SDAD1. Cell Mol Biol Lett. 2017;22:12.CrossRefPubMedPubMedCentral
2.
Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, van de Velde CJH, Watanabe T. Colorectal cancer. Nat Rev Dis Primers. 2015;1:15065.CrossRefPubMedPubMedCentral
3.
4.
Sun Z, Shi K, Yang S, Liu J, Zhou Q, Wang G, Song J, Li Z, Zhang Z, Yuan W. Effect of exosomal miRNA on cancer biology and clinical applications. Mol Cancer. 2018;17(1):147.CrossRefPubMedPubMedCentral
5.
Wang J, Li H, Wang Y, Wang L, Yan X, Zhang D, Ma X, Du Y, Liu X, Yang Y. MicroRNA-552 enhances metastatic capacity of colorectal cancer cells by targeting a disintegrin and metalloprotease 28. Oncotarget. 2016;7(43):70194–210.CrossRefPubMedPubMedCentral
6.
Chen J, Wang W, Zhang Y, Hu T, Chen Y. The roles of miR-200c in colon cancer and associated molecular mechanisms. Tumour Biol. 2014;35(7):6475–83.CrossRefPubMed
7.
Huang GL, Sun J, Lu Y, Liu Y, Cao H, Zhang H, Calin GA. MiR-200 family and cancer: from a meta-analysis view. Mol Asp Med. 2019;70:57–71.CrossRef
8.
Gao Z, Zhou H, Wang Y, Chen J, Ou Y. Regulatory effects of lncRNA ATB targeting miR-200c on proliferation and apoptosis of colorectal cancer cell. J Cell Biochem. 2020;121(1):332–43.CrossRefPubMed
9.
Karimi MM, Tavangar SM, Saidijam M, Amini R, Bahreini F, Karimi DF, Najafi R. Anticancer effects of miR-200c in colorectal cancer through BMI1. J Cell Biochem. 2018;119(12):10005–12.CrossRef
10.
Ast V, Kordaß T, Oswald M, et al. MiR-192, miR-200c and miR-17 are fibroblast-mediated inhibitors of colorectal cancer invasion. Oncotarget. 2018;9(85):35559–80.CrossRefPubMedPubMedCentral
11.
Hur K, Toiyama Y, Takahashi M, Balaguer F, Nagasaka T, Koike J, Hemmi H, Koi M, Boland CR, Goel A. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut. 2013;62(9):1315–26.CrossRefPubMed
12.
13.
Shu C, Yan D, Mo Y, Gu J, Shah N, He J. Long noncoding RNA lncARSR promotes epithelial ovarian cancer cell proliferation and invasion by association with HuR and miR-200 family. Am J Cancer Res. 2018;8(6):981–92.PubMedPubMedCentral
14.
Ghahhari NM, Babashah S. Interplay between microRNAs and WNT/β-catenin signalling pathway regulates epithelial-mesenchymal transition in cancer. Eur J Cancer. 2015;51(12):1638–49.CrossRefPubMed
15.
Dermani FK, Amini R, Saidijam M, Pourjafar M, Saki S, Najafi R. Zerumbone inhibits epithelial-mesenchymal transition and cancer stem cells properties by inhibiting the β-catenin pathway through miR-200c. J Cell Physiol. 2018;233(12):9538–47.CrossRefPubMed
16.
Liu Y, Zhu ST, Wang X, et al. MiR-200c regulates tumor growth and chemosensitivity to cisplatin in osteosarcoma by targeting AKT2. Sci Rep. 2017;7(1):13598.CrossRefPubMedPubMedCentral
17.
Li S, Ren Q. Effects of arsenic on wnt/β-catenin signaling pathway: a systematic review and meta-analysis. Chem Res Toxicol. 2020;33(6):1458–67.CrossRefPubMed
18.
Roh MS, Lee HW, Jung SB, et al. Expression of miR-200c and its clinicopathological significance in patients with colorectal cancer. Pathol Res Pract. 2018;214(3):350–5.CrossRefPubMed
19.
Yu C, Wan H, Shan R, et al. The prognostic value of the MiR-200 family in colorectal cancer: a meta-analysis with 1882 patients. J Cancer. 2019;10(17):4009–16.CrossRefPubMedPubMedCentral
20.
Giordano G, Febbraro A, Tomaselli E, et al. Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer. J Exp Clin Cancer Res. 2015;34:108.CrossRefPubMedPubMedCentral
21.
Zidar N, Boštjančič E, Jerala M, et al. Down-regulation of microRNAs of the miR-200 family and up-regulation of snail and slug in inflammatory bowel diseases - hallmark of epithelial-mesenchymal transition. J Cell Mol Med. 2016;20(10):1813–20.CrossRefPubMedPubMedCentral
22.
Zheng Q, Cui X, Zhang D, et al. miR-200b inhibits proliferation and metastasis of breast cancer by targeting fucosyltransferase IV and α1,3-fucosylated glycans. Oncogenesis. 2017;6(7):e358.CrossRefPubMedPubMedCentral
23.
Blanas A, Cornelissen LAM, Kotsias M, van der Horst JC, van de Vrugt HJ, Kalay H, Spencer DIR, Kozak RP, van Vliet SJ. Transcriptional activation of fucosyltransferase (FUT) genes using the CRISPR-dCas9-VPR technology reveals potent N-glycome alterations in colorectal cancer cells. Glycobiology. 2019;29(2):137–50.CrossRefPubMed
24.
Liu B, Ma H, Liu Q, et al. MiR-29b/Sp1/FUT4 axis modulates the malignancy of leukemia stem cells by regulating fucosylation via Wnt/β-catenin pathway in acute myeloid leukemia. J Exp Clin Cancer Res. 2019;38(1):200.CrossRefPubMedPubMedCentral
Metadata
Title
RETRACTED ARTICLE: MiR-200c/FUT4 axis prevents the proliferation of colon cancer cells by downregulating the Wnt/β-catenin pathway
Authors
Jinchun Cong
Jian Gong
Chuanjia Yang
Zhixiu Xia
Hong Zhang
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-07670-y

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue

Research

Direct comparisons of efficacy and safety between actinomycin-D and methotrexate in women with low-risk gestational trophoblastic neoplasia: a meta-analysis of randomized and high-quality non-randomized studies

Research article

A novel scoring system integrating molecular abnormalities with IPSS-R can improve the risk stratification in patients with MDS

Research

The development and validation of the psychological capital questionnaire for patients with Cancer the psychological capital questionnaire

Research

High HSPA8 expression predicts adverse outcomes of acute myeloid leukemia

Research article

Clinical outcomes of bulky parotid gland cancers: need for self-examination and screening program for early diagnosis of parotid tumors

Research

Prognostic significance of the postoperative prognostic nutritional index in patients with glioblastoma: a retrospective study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits